Antiretroviral therapy in HIV-positive women is associated with increased apolipoproteins and total cholesterol

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 3, 2006, Pages 307-313

  Rimland, David ^a,b   Guest, Jodie L ^a   Hernández Ramos, Isabel ^b,c   Del Rio, Carlos ^b,c   Le, N Anh ^b   Brown, W Virgil ^a,b  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

ARV therapy; HIV; Lipoproteins; Triglycerides

Indexed keywords

ABACAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; PREVALENCE; PRIORITY JOURNAL; SMOKING; STATISTICAL SIGNIFICANCE; VASCULAR DISEASE;

ADULT; AGED; ANTI-HIV AGENTS; APOLIPOPROTEINS; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; TRIGLYCERIDES;

EID: 33745910543     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000220164.72113.12     Document Type: Article

References (56)

1. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13(18):2493-2505.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
3. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353(9170):2093-2099.
4. Rhew DC, Bernal M, Aguilar D, et al. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Clin Infect Dis. 2003;37:959-972.
5. Rimland D, Guest JL, Hernandez I, et al. Antiretroviral therapy in HIV positive men is associated with increased apoCIII in triglyceride rich lipoproteins. HIV Med. 2005;6:326-333.
6. Thiebaut R, Dabis F, Malvy D, et al. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine cohort, France, 1996 to 1998. J Acquir Immune Defic Syndr. 2000;23:261-265.
7. Batterham MJ, Garsia R, Greenop PA. Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy 'Diet FRS Study'. AIDS. 2000;14:1839-1843.
8. Roberts A, Muesing RA, Parenti DM, et al. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis. 1999;29:441-443.
9. Koppel K, Bratt G, Eriksson M, et al. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection. Int J STD AIDS. 2000;11(7):451-455.
10. Bonnet F, Saves M, Roz C, et al. Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens. J Acquir Immune Defic Syndr. 2000;25:199-200.
11. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr. 2005;39:44-54.
12. Dong K, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr. 1999;21:107-113.
13. Pernerstorfer-Schoen H, Jilma B, Perschler A, et al. Sex differences in HAART-associated dyslipidemia. AIDS. 2001;15:725-734.
14. Gervasoni C, Ridolfo A, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465-471.
15. Tien P, Cole S, Williams C, et al. Incidence of lipoatrophy and lipohypertrophy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2003;34:461-466.
16. Galli M, Veglia F, Anagarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. J Acquir Immune Defic Syndr. 2003;34(1):58-61.
17. Kotler DP, Lopes J, Engelson E, et al. Interactions among sex, HIV infection and fat redistribution. AIDS Read. 2000;10:589-594.
18. Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003 July 15;37:292-298.
19. Fontas E, van Leth F, Sabin C, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056-1074.
20. Martinez E, Domingo P, Galindo M, et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis. 2004;38:1017-1023.
21. Behrens G, Schmidt HH, Stoll M, et al. ApoE genotype and protease-inhibitor-associated hyperlipidaemia. [comment]. Lancet. 1999;354(9172):76.
22. Palacios R, Santos J, Ruiz M. Short-term lipid changes associated with highly active antiretroviral therapy in naive HIV-infected patients. J Acquir Immune Defic Syndr. 2003;34:249-251.
23. Bonnet E, Ruidavets J-B, Tuech J, et al. Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endocrinol Metab. 2001;86:296-302.
24. Lee G, Rao M, Grunfeld C. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr Infect Dis Rep. 2004;6:471-482.
25. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179-1193.
26. Matthews G, Moyle GJ, Mandalia S, et al. Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy. J Acquir Immune Defic Syndr. 2000;24:310-315.
27. Manfredi R, Claza L, Chiodo F. An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. J Acquir Immune Defic Syndr. 2005;38(2):236-238.
28. Van Der Valk M, Kastelein J, Murphy R, et al. Nevirapine-containing antiretroviral therapy in HIV-1-infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15:2407-2414.
29. Negredo E, Ribalta J, Ferre R, et al. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. AIDS. 2004;18:819-821.
30. Gallant J, Staszewski S, Pozniak AL. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
31. Rodriguez C, Pablos-Mendez A, Palmas W, et al. Comparison of modifiable determinants of lipids and lipoprotein levels among African-Americans, Hispanics, and non-Hispanic Caucasians > or =65 years of age living in New York City. Am J Cardiol. 2002;89(2):178-183.
32. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
33. Kamin DS, Grinspoon S. Cardiovascular disease in HIV-positive patients. AIDS. 2005;19:641-652.
34. Smith C, Levy I, Sabin C, et al. Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. HIV Med. 2004;5:88-92.
35. El-Sadr W, Neaton J, Neuhaus J, et al. Comparison of risk factors for coronary heart disease among men and women enrolled in the SMART study (CPCRA 065). Paper presented at: 10th Conference on Retroviruses and Opportunistic Infections; February, 2003; Boston, MA.
36. Matetzky S, Domingo M, Kar S, et al. Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med. 2003;163(4):457-460.
37. Sullivan AK, Nelson MR, Moyle GJ, et al. Coronary artery disease occurring with protease inhibitor therapy. Int J STD AIDS. 1998;9(11):711-712.
38. Passalaris J, Sepkowitz K, Glesby M. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis. 2000;31:787-797.
39. Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS. 2000;14:123-128.
40. Meng Q, Lima J, Lai H, et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J. 2002;144(4):642-648.
41. Hsue P, Lo J, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109:1603-1608.
42. Talwani R, Falusi OM, Mendes de Leon C, et al. Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;30(2):191-195.
43. Floris-Moore M, Lo Y, Klein R, et al. Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;34(3):331-337.
44. Fisher SD, Lipshultz SE. Epidemiology of cardiovascular involvement in HIV disease and AIDS. Ann N Y Acad Sci. 2001;946:13-22.
45. Klein D, Hurley LB, Quesenberry CP, et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471-477.
46. Bozzette S, Ake C, Tam H, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003 February 20;348:702-710.
47. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
48. Iloeje U, Yuan Y, L'Italien G, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med. 2005;6:37-44.
49. Friis-Moller N, Sabin C, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
50. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J. 1986;112:432-437.
51. Assman MD, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733-737.
52. Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride levels and mortality from coronary heart disease. N Engl J Med. 1993;328:1220-1225.
53. Le N-A, Brown WV, Davis WW, et al. Comparison of the relation of triglyceride-rich lipoproteins and muscular artery compliance in healthy women versus healthy men. Am J Cardiol. 2005;95:1049-1054.
54. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;1994:42-49.
55. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102(16):1886-1892.
56. Luc G, Fievet C, Arveiler D, et al. Apolipoproteins C-III and E in apoB-and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. J Lipid Res. 1996;37:508-517.